Alkermes (NASDAQ:ALKS) issued an update on its FY17 earnings guidance on Wednesday morning. The company provided EPS guidance of $0.03-0.22 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.12. The company issued revenue guidance of $870-900 million, compared to the consensus revenue estimate of $882.79 million.

Shares of Alkermes (NASDAQ:ALKS) opened at $56.64 on Wednesday. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23. Alkermes has a 1-year low of $46.42 and a 1-year high of $63.40. The company has a market capitalization of $8,710.00, a price-to-earnings ratio of -51.03 and a beta of 2.13.

Alkermes (NASDAQ:ALKS) last released its earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The business had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. During the same period in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 20.6% compared to the same quarter last year. sell-side analysts anticipate that Alkermes will post -0.59 EPS for the current fiscal year.

ALKS has been the topic of several analyst reports. Mizuho set a $81.00 target price on Alkermes and gave the stock a buy rating in a report on Saturday, October 21st. Credit Suisse Group set a $66.00 target price on Alkermes and gave the stock a buy rating in a report on Tuesday, November 28th. ValuEngine downgraded Alkermes from a hold rating to a sell rating in a report on Monday, October 23rd. Zacks Investment Research raised Alkermes from a hold rating to a buy rating and set a $61.00 target price on the stock in a report on Monday. Finally, UBS Group set a $54.00 target price on Alkermes and gave the stock a hold rating in a report on Friday, October 27th. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Alkermes presently has a consensus rating of Hold and a consensus target price of $63.33.

In related news, SVP Michael J. Landine sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $48.71, for a total transaction of $730,650.00. Following the completion of the sale, the senior vice president now owns 178,693 shares in the company, valued at $8,704,136.03. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard F. Pops sold 50,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $48.87, for a total value of $2,443,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 136,417 shares of company stock worth $7,259,391. Corporate insiders own 5.34% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Alkermes (ALKS) Issues FY17 Earnings Guidance” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Earnings History and Estimates for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with's FREE daily email newsletter.